false
0001385818
0001385818
2026-11-16
2026-11-16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
November 16, 2026
Date of Report (Date of earliest event reported):
AYTU BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-38247
|
|
47-0883144
|
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
7900 East Union Avenue, Suite 920
Denver, CO 80237
(Address of principal executive offices, including zip code)
(720) 437-6580
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☒
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
|
Trading Symbol(s)
|
|
Name of Each Exchange on Which Registered
|
|
Common Stock, par value $0.0001 per share
|
|
AYTU
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On November 16, 2026, Aytu BioPharma Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Rosemont Pharmaceuticals Holdings, Inc., a Delaware corporation (“Parent”), and RoseApollo Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”). The Merger Agreement provides for the acquisition of the Company by Parent in a two-step transaction, consisting of a tender offer and, subject to the terms of the Merger Agreement and conditioned upon the consummation of the Offer, a subsequent merger of Purchaser with and into the Company (the “Merger”), with the Company continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.
Pursuant to the Merger Agreement, Purchaser will commence a tender offer (the “Offer”) as promptly as practicable after the date of the Merger Agreement, and in any event no later than ten business days after the date of the Merger Agreement, to acquire (subject to the terms and conditions of the Merger Agreement) all of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Shares”), for $2.70 per Share, net to the seller in cash, without interest (the “Offer Price”), subject to applicable tax withholding. Unless extended in accordance with the Merger Agreement, the Offer will expire one minute after 11:59 p.m., New York City time, on the twentieth day (calculated as set forth in Rule 14d-1(g)(3) under the Exchange Act (as defined below)) following and including the commencement of the Offer (subject to extension as set forth in the Merger Agreement). The Company’s board of directors (the “Company Board”) and a special committee of the Company Board has unanimously recommended that the Company’s stockholders accept the Offer and tender their Shares to Purchaser pursuant to the Offer.
The obligation of Parent and Purchaser to consummate the Offer is subject to the satisfaction or waiver, to the extent permitted, of certain conditions set forth in the Merger Agreement, including that there have been validly tendered and not validly withdrawn a number of Shares that, together with Shares beneficially owned by Parent, Purchaser and their wholly owned subsidiaries, represent a majority of the Shares outstanding as of the consummation of the Offer. In addition, Purchaser’s obligation to consummate the Offer is conditioned upon, among other things, the accuracy of the Company’s representations and warranties, subject to specified materiality standards; the Company’s material compliance with its covenants; the absence of a Company material adverse effect; all required third-party consents having been obtained; Parent’s receipt of customary payoff letters for outstanding Payoff Debt (as defined in the Merger Agreement); and no greater than 15% of the Company Warrants (as defined in the Merger Agreement), measured by the number of underlying Shares, remain outstanding without having been exercised prior to the Expiration Date (as defined in the Merger Agreement) with all Shares issued upon such exercise validly tendered and not withdrawn pursuant to the Offer pursuant to a Company Warrant Exercise Agreement (as defined in the Merger Agreement), or terminated pursuant to a Support Agreement (as defined below) or Company Warrant Termination Agreement (as defined in the Merger Agreement). Consummation of the Offer is not subject to a financing condition.
As soon as practicable following Purchaser’s acceptance for payment of the Shares validly tendered and not validly withdrawn pursuant to the Offer (the “Acceptance Time”), subject to the satisfaction or waiver of limited customary conditions set forth in the Merger Agreement, the Merger will be effected under Section 251(h) of the Delaware General Corporation Law (the “DGCL”), without a meeting or vote of the Company’s stockholders.
At the effective time of the Merger (the “Effective Time”), each issued and outstanding Share, other than Shares held by the Company as treasury stock, Shares held directly by Parent or Purchaser or any direct or indirect wholly owned subsidiary of the Company, Parent or Purchaser, and Shares whose holders have properly exercised and perfected appraisal rights under Section 262 of the DGCL, will not be converted into the right to receive the Offer Price in cash (the “Merger Consideration”).
Effective immediately prior to the Effective Time, each outstanding option to purchase Shares (each, a “Company Option”) shall, to the extent not vested, automatically become fully vested in connection with the consummation of the transactions contemplated in the Merger Agreement pursuant to the terms of the underlying award agreements governing each such Company Option and will be automatically cancelled and converted into the right to receive, without interest and less applicable tax withholding, a lump-sum cash payment equal to the number of Shares underlying the Company Option multiplied by the excess, if any, of the Merger Consideration over the applicable per-Share exercise price. Each Company Option with a per-Share exercise price equal to or greater than the Merger Consideration will be cancelled for no consideration; provided that, before cancellation, the Company will provide holders at least ten days to exercise their Company Options (and shall accelerate the vesting of any such Company Options, to the extent unvested, that are so exercised, prior to such exercise).
Effective immediately prior to the Effective Time, the vesting restrictions and requirements of forfeiture with respect to each outstanding Share that is subject to vesting, repurchase or other lapse restrictions, whether granted under a Company Equity Plans (as defined in the Merger Agreement) or otherwise (each, a “Company Restricted Share”), shall have terminated and such Company Restricted Shares shall be treated as Shares in accordance with the Merger Agreement; provided, that any Company Restricted Shares held by an employee of the Company or its applicable Subsidiary that is not the subject of a timely and validly filed election under Section 83(b) of the Internal Revenue Code of 1986, as amended, shall be paid the applicable Merger Consideration (less any applicable withholding taxes) within the later of fifteen business days following the closing date and the Surviving Corporation’s (as defined in the Merger Agreement) next regular payroll date (but in no event earlier than the date of receipt of file-stamped evidence of the Merger filing from the Secretary of State of the State of Delaware).
Effective as of, and conditional upon the occurrence of, the Effective Time, the Company Equity Plans (as defined in the Merger Agreement) and Company ESPP (as defined in the Merger Agreement) shall be terminated. All rights under the Company Equity Plans outstanding immediately prior to the Effective Time shall cease to be outstanding, except the right to receive the consideration set forth in the Merger Agreement.
The Company is required to use reasonable best efforts to cause each holder of a Company Warrant that is not a party to a Support Agreement to exercise its Company Warrants before the applicable deadline, pursuant to a Company Warrant Exercise Agreement or enter into a Company Warrant Termination Agreement. Each Company Warrant subject to a Company Warrant Termination Agreement or Support Agreement will be cancelled immediately prior to the Effective Time in exchange for the cash consideration specified in the applicable agreement. Each Company Warrant (as defined in the Merger Agreement) that is outstanding and unexercised immediately prior to the Effective Time and for which a Support Agreement, Company Warrant Termination Agreement or Company Warrant Exercise Agreement has not been delivered shall be treated in accordance with its terms.
The Merger Agreement contains representations, warranties and covenants of the parties customary for a transaction of this nature. Subject to the terms and conditions of the Merger Agreement, the parties have agreed to use reasonable best efforts to consummate the Offer, the Merger and the other transactions contemplated by the Merger Agreement, including obtaining required governmental authorizations, making required governmental filings and obtaining required third-party consents. The Company has agreed that, subject to specified exceptions, during the period from the date of the Merger Agreement until the earlier of the Effective Time and valid termination of the Merger Agreement, among other things, the Company will conduct its business in the ordinary course consistent with past practice and will not take certain specified actions without Parent’s prior written consent. The Company has also agreed to customary non-solicitation restrictions, including not to solicit, initiate or knowingly induce, encourage or facilitate a Takeover Proposal (as defined in the Merger Agreement) from a third part or effect a Company Adverse Recommendation Change (as defined in the Merger Agreement).
The Merger Agreement also includes customary termination provisions for both the Company and Parent, including, among others, the right of both parties to terminate for failure to consummate the Offer on or before February 14, 2027, being the 90th day after the date of the Merger Agreement. The Company is required to pay Parent a termination fee of $2.4 million upon termination of the Merger Agreement in specified circumstances, including if the Company terminates the Merger Agreement to enter into a definitive agreement for a Superior Proposal (as defined in the Merger Agreement) or if Parent terminates the Merger Agreement following a Company Adverse Recommendation Change. The Termination Fee will also be payable if the Merger Agreement is terminated in certain other specified circumstances, a qualifying Takeover Proposal was publicly disclosed and not timely withdrawn before termination, and, within twelve months after termination, the Company enters into a definitive agreement fora qualifying Takeover Proposal that is later consummated, or consummates a qualifying Takeover Proposal.
The representations and warranties of the Company contained in the Merger Agreement were made solely for the benefit of Parent and Purchaser and only for purposes of the Merger Agreement. They are subject to qualifications and disclosures, including certain information in Company filings and certain submissions to the U.S. Securities and Exchange Commission (the “SEC”), and to contractual standards of materiality that may differ from those generally applicable to investors. They speak only as of the date of the Merger Agreement or such other date as may be specified therein and were included for purposes of allocating contractual risk among the parties rather than establishing matters as facts. Accordingly, investors should not rely on the representations and warranties or descriptions thereof as characterizations of the actual state of facts or condition of the parties or their respective subsidiaries or affiliates. Information concerning their subject matter may change after the date of the Merger Agreement and may or may not be fully reflected in the Company’s public disclosures. The Merger Agreement should be read together with the Company’s Forms 10-K, Forms 10-Q, Forms 8-K, proxy statements and other documents filed with the SEC, including filings made in connection with the Offer.
The foregoing description of the Merger Agreement is not complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which is filed as Exhibit 2.1 to this Current Report on Form 8-K and incorporated herein by reference. The Merger Agreement is not intended to provide any other factual information about the Company, Parent or Purchaser, their respective businesses, or the actual conduct of their respective businesses during the period prior to the consummation of the Offer, the Merger or otherwise.
Tender and Support Agreements
On November 16, 2026, concurrently with the execution and delivery of the Merger Agreement, certain officers, all of the directors and certain stockholders of the Company entered into tender and support agreements (collectively, “Support Agreements”) with Parent and Purchaser. Subject to the terms and conditions of the Support Agreements, those stockholders agreed to, among other things, tender all Shares beneficially owned by them into the Offer and to terminate their Company Warrants as of the Effective Time in exchange for the consideration set forth in the applicable Support Agreement.
The foregoing description of the Support Agreements does not purport to be complete and is qualified in its entirety by reference to the form of Support Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 7.01 Regulation FD Disclosure
On November 16, 2026, the Company issued a press release announcing the execution of the Merger Agreement described above. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information contained in the accompanying Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information contained in the press release shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Important Information for Investors and Stockholders
The Offer has not yet commenced. This document is for informational purposes only and is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell any securities of the Company or any other entity, nor is it a substitute for any tender offer materials that Parent, Purchaser or the Company will file with the SEC. A solicitation and an offer to buy securities of the Company will be made only pursuant to an offer to purchase and related materials that Parent and Purchaser intend to file with the SEC. At the time the Offer is commenced, Parent and Purchaser will file a Tender Offer Statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, with the SEC, and the Company thereafter will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the Offer. THE COMPANY’S SECURITYHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 REGARDING THE OFFER, AS THEY MAY BE AMENDED FROM TIME TO TIME, WHEN THEY BECOME AVAILABLE CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITYHOLDERS SHOULD READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE OFFER. The offer to purchase, the related letter of transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, will be sent to all stockholders of the Company at no expense to them.
Cautionary Statement Regarding Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking statements”. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” “believes,” and similar expressions intended to identify forward-looking statements. These statements reflect the Company’s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements include, without limitation, statements regarding the Offer, the Merger and other related matters; prospective performance and opportunities; post-closing operations and the outlook for the businesses of the Company and Parent, including, without limitation, results from clinical trials, regulatory applications and related timelines, and the ability of Parent to advance the Company’s product pipeline; and any assumptions underlying any of the foregoing. The following are some of the factors that could cause actual future results to differ materially from those expressed in any forward-looking statements: (i) uncertainties as to the timing of the Offer and the Merger; (ii) the risk that the Offer or the Merger may not be completed in a timely manner or at all; (iii) uncertainties as to the percentage of the Company’s stockholders tendering their shares in the Offer; (iv) the possibility that competing offers or acquisition proposals for the Company will be made; (v) the possibility that any or all of the various conditions to the consummation of the Offer or the Merger may not be satisfied or waived, including the failure to receive any approvals from any applicable third-parties; (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, including in circumstances which would require the Company to pay a termination fee or other expenses; (vii) the effect of the announcement or pendency of the transactions contemplated by the Merger Agreement on the Company’s business, its ability to retain and hire key personnel, its ability to maintain relationships with its suppliers and others with whom it does business, or its operating results and business generally; (viii) risks related to diverting management’s attention from the Company’s ongoing business operations; (ix) the risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability; and (x) other factors as set forth from time to time in the Company’s filings with the SEC, including the Company’s Solicitation/Recommendation Statement on Schedule 14D-9 to be filed with the SEC in connection with the Offer, its Form 10-K for the fiscal year ended June 30, 2026 and any subsequent Form 10-Qs. Any forward-looking statements set forth in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K. The Company does not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit
|
|
Description
|
|
2.1*
|
|
Agreement and Plan of Merger, dated as of November 16, 2026, by and among the Company, Parent, and Purchaser
|
|
10.1
|
|
Form of Tender and Support Agreements
|
|
99.1
|
|
Press Release issued by the Company, dated November 16, 2026
|
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* Schedules, exhibits and annexes to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish copies of any of the omitted schedules, exhibits and annexes upon request by the SEC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
AYTU BIOPHARMA, INC.
|
| |
|
| |
|
|
Date: November 16, 2026
|
By:
|
/s/ Ryan J. Selhorn
|
| |
|
Ryan J. Selhorn
|
| |
|
Chief Financial Officer
|
Exhibit 99.1
Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer
Agreement with Rosemont Pharmaceuticals provides for all-cash consideration of $2.70 per share
Tender offer price represents 41.1% premium to 30-day volume-weighted average price and 51.7% premium to the closing price on November 13, 2026
Tender offer support agreements secured from Nantahala Capital Management, Stonepine Capital Management and Aytu’s directors and officers
Closing is anticipated to occur by the end of calendar year 2026, subject to the satisfaction or waiver of the conditions to the tender offer
DENVER, CO / November 16, 2026 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it has entered into a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc. (“Rosemont”), pursuant to which Rosemont would acquire Aytu, through a tender offer for $2.70 per share.
Under the terms of the merger agreement, a wholly-owned subsidiary of Rosemont will commence a tender offer to acquire all outstanding shares of Aytu common stock. The transaction is structured as a tender offer to be followed by a merger, subject to customary conditions to the tender offer and merger, including the tender of shares representing at least a majority of the total number of outstanding shares of Aytu common stock and the exercise or termination of certain outstanding warrants. Following the successful completion of the tender offer, Rosemont will acquire all remaining shares not tendered in the tender offer (other than shares for which appraisal rights are properly exercised) through a second-step merger at the same price paid in the tender offer.
Rosemont intends to commence the tender offer and file a Schedule TO within 10 business days, and Aytu will file a Schedule 14D-9 with respect to the tender offer substantially concurrently with the commencement of the tender offer, each of which will include additional details on the transaction and process undertaken by the Company.
The transaction was unanimously approved by the Aytu board of directors and closing is anticipated to occur in late December 2026, subject to the satisfaction or waiver of the conditions to the tender offer. Aytu’s executive officers, directors and certain stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management, have signed tender and support agreements under which such stockholders agreed, among other things, to tender their shares in the tender offer and to the termination or exercise of any warrants held by them prior to the Effective Time, in exchange for the consideration payable in connection with the transaction in accordance with the terms of such warrants.
Josh Disbrow, Chief Executive Officer of Aytu BioPharma, said: “This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve. We see a strong strategic fit between our portfolio and Rosemont’s experience developing and commercializing specialty medicines. Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”
Alok Sonig, Chief Executive Officer of Rosemont Pharmaceuticals, said: “The proposed acquisition of Aytu marks an important step in Rosemont’s US growth strategy. Aytu has built an established CNS adult and pediatric-focused specialty pharmaceutical business with talented people, a differentiated portfolio and proven commercial capabilities. Together with Rosemont’s product development, regulatory, manufacturing and commercial expertise, we believe we can build a strong platform for future growth. We look forward to welcoming the Aytu team once the transaction is complete.”
Canaccord Genuity is acting as financial advisor to Aytu BioPharma. Dorsey & Whitney LLP is serving as legal counsel to Aytu in connection with the transaction. Bourne Partners is acting as financial advisor to Rosemont. Ropes & Gray LLP is serving as legal counsel to Rosemont.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. Aytu’s prescription products include EXXUA® (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention-deficit/hyperactivity disorder (ADHD). Aytu is committed to delivering its medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
About Rosemont Pharmaceuticals
Rosemont Pharmaceuticals is a global pharmaceutical company specialising in the development, manufacture and supply of oral liquid medicines. For nearly 60 years, Rosemont has focused on creating alternative dosage forms that help address the needs of patients who may have difficulty swallowing solid oral medicines.
Through its broad portfolio across multiple therapeutic areas, Rosemont works to support patients, caregivers and healthcare professionals by improving access to medicines in formulations designed to meet diverse patient needs. Rosemont Pharmaceuticals is headquartered in Leeds in the United Kingdom and serves patients across international markets through a growing portfolio of licensed medicines.
For more information, please visit: www.rosemontpharma.com
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: uncertainties as to the timing of the tender offer and the merger; uncertainties as to how many Aytu stockholders will tender their shares in the tender offer; the possibility that the conditions to the tender offer and the merger may not be satisfied or waived; the occurrence of any event that could give rise to the termination of the merger agreement; the effects of the transaction on relationships with employees, customers, suppliers and other business partners; potential stockholder litigation or regulatory action relating to the transaction; the Company’s overall financial and operational performance, potential adverse changes to the Company’s financial position or its business, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of its products, its partners performing their required activities, its anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaborations. The Company also refers you to the risks described in “Risk Factors” in Part I, Item 1A of the Company’s most recent Annual Report on Form 10-K and in the other reports and documents it files with the United States Securities and Exchange Commission, as well as the tender offer documents to be filed by Rosemont and the Schedule 14D-9 to be filed by the Company.
Additional Information and Where to Find It
The tender offer for all of the outstanding shares of Aytu described in this communication has not yet commenced. This press release is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Rosemont and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. A solicitation and offer to buy outstanding shares of Aytu will only be made pursuant to the tender offer materials that Rosemont and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced, Rosemont and its acquisition subsidiary will file tender offer materials on Schedule TO, and Aytu will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF AYTU ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF AYTU SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all stockholders of Aytu at no expense to them on the SEC’s website at www.sec.gov and (once they become available) will be mailed to the stockholders of Aytu free of charge. Additional copies may be obtained for free by contacting Aytu, or by contacting Sodali & Co, the information agent for the Offer, toll-free at (800) 662-5200 or at AYTU.info@investor.sodali.com. The information contained in, or that can be accessed through, the SEC’s website is not a part of, or incorporated by reference herein. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Aytu files annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Aytu with the SEC for free on the SEC’s website at www.sec.gov.
Contacts for Aytu
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com